JPRN-jRCT2051210126进行中（未招募）2 期
A randomized, multicenter, double-blind, placebo-controlled clinical trial of sirolimus gel in cutaneous manifestation of patients with vascular
Jinnin Masatoshi0 个研究点目标入组 50 人开始时间: 2021年11月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 01month old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients who are at least one month old
- •2)Patients with skin lesions diagnosed as venous malformation or lymphatic malformation (lymphangioma or lymphangiomatosis) according to the criteria by center for specific pediatric chronic diseases, or diagnosed as tufted hemangioma or Kaposiform hemangioendothelioma according to Japanese clinical practice guidelines for vascular anomalies 2017
- •3)Patients with target lesions that do not show a tendency to disappear within 4 weeks of interview and are visible on photographs.
- •4)Patients for whom written consent for participation in the study has been obtained from the subject and/or a substitute (if the subject is under 20 years of age at the time of obtaining consent).
- •5)Patients who have no intention to participate in other clinical trials, clinical studies, or observational studies while participating in this study
排除标准
- •1)Patients who have received oral treatment with mTOR inhibitors (sirolimus, everolimus, temsirolimus, etc.) within 12 weeks prior to registration
- •2)Patients who have participated in other clinical trials within 6 months prior to registration
- •3)Patients who have received treatment for the target lesion (surgical, endovascular, laser, phototherapy, liquid nitrogen therapy, elastic bandage) within 3 months prior to registration
- •4)Patients who have received drugs used for the treatment of the target disease, such as immunosuppressive agents (oral and topical), anticancer drugs, propranolol, radiotherapy, steroid pulse therapy, oral steroids for more than one month, interferon, Yuexuekazhu Tang, Huangqi Jianzhong Tang, etc., within 3 months prior to registration
- •5)Patients with skin lesions such as severe erosions or ulcers on the target lesion
- •6)Patients with significant bleeding in the target lesion
- •7)Patients with infectious diseases in the target lesion
- •8)Patients with malignant tumors, infections, serious cardiac, hepatic, renal, or hematological diseases (determined by the investigator referring to grade 2 or higher in the Japanese translation of CTCAEv5.0 JCOG)
- •9)Patients with a history of allergy to sirolimus, macrolide antibiotics, or additives used in the investigational product
- •10)Patients with immunodeficiency such as HIV, primary immunodeficiency, etc.
- •11)Patients who fall under at least one of the following
- •Pregnant or may be pregnant
- •Breast-feeding
- •Do not agree to use contraception during this study
- •12)Patients who do not agree to avoid direct sunlight to the application site during this study
- •13)Patients who are judged by the investigator to be inappropriate for this study
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the use of Ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in patients with metastatic pancreatic adenocarcinomametastatic pancreatic adenocarcinomaMedDRA version: 18.1 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2015-000905-38-FRPharmacyclics LLC326
进行中（未招募）
1 期
A study to evaluate the use of Ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in patients with metastatic pancreatic adenocarcinomametastatic pancreatic adenocarcinomaMedDRA version: 18.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2015-000905-38-ESPharmacyclics LLC326
进行中（未招募）
1 期
A study to evaluate the use of Ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in patients with metastatic pancreatic adenocarcinomametastatic pancreatic adenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2015-000905-38-ITPHARMACYCLICS SWITZERLAND GMBH424
进行中（未招募）
1 期
A study to evaluate the use of Ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in patients with metastatic pancreatic adenocarcinomametastatic pancreatic adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2015-000905-38-DEPharmacyclics LLC426
进行中（未招募）
1 期
A study to evaluate the use of Ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in patients with metastatic pancreatic adenocarcinomametastatic pancreatic adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000016906EUCTR2015-000905-38-BEPharmacyclics LLC426